Topic:
R&D
Latest Headlines
Latest Headlines
CytRx dumps failed IIb trial for lung cancer, focuses on aldoxorubicin
CytRx has decided to dump a Phase IIb lung cancer study for the number-two drug program in the pipeline after the monitoring committee concluded that the trial was unlikely to find any improvement in progression-free survival compared to standard treatments.
Behold the patent cliff: U.S. drug market shrinks for first time
U.S. drug spending dropped last year. While that may be welcome news for healthcare budgets, it's not so good for branded drugmakers. It may not be so good for patients, either.
Medtronic's Ishrak: Renal denervation hasn't caught on yet in Europe
Medtronic has generated plenty of buzz about its renal denervation technology, which is designed to deaden the nerves in the kidneys to combat drug-resistant hypertension. But it has been slow to catch on in Europe, where reimbursement struggles remain.
Which Big Biotechs are hitting the gas pedal on R&D spending?
The R&D numbers for the top 10 biotechs may only amount to a fraction of what you'll find in Big Pharma. But unlike the giants, which are trying to keep a lid on multibillion-dollar budgets, you'll find a much faster crowd when you turn your gaze to the biotechs.
Genomics, Biotechnology's Oldest Next Big Thing
The economist Edward Fiedler famously said "He who lives by the crystal ball soon learns to eat ground glass," a statement to whose veracity I can readily attest having written widely on the potential of genomics during my tenure on Wall Street. Read the feature >>
Hong Kong billionaire backs Big Data effort in biomedicine at Oxford University
Oxford University is marshaling money and scientists to explore massive datasets to uncover knowledge about diseases and treatments.
UPDATED: Takeda beefs up new vaccines arm with $250M bolt-on buyout of Inviragen
A couple of months after moving its experimental dengue vaccine into the second phase of a mid-stage study, Fort Collins, CO-based Inviragen has been snapped up by Takeda in a $250 million deal.
Langer's Kala touts positive results for topical wet AMD treatment
Kala Pharmaceuticals is developing a novel way to get drugs into the eye, and the company notched some positive results in preclinical studies, finding that its platform led to higher drug concentration for a retinal treatment.
UPDATED: Biotech trio to take over Alderley labs as AstraZeneca heads south
It's the start of what locals hope will be a continued migration of smaller companies to the Alderley campus to fill the void of AZ's massive exit from the area.
GlaxoSmithKline's 'independent experts' start to hand out keys to its data vault
Despite a major backlash in the industry, GSK has agreed to open up the data vault to investigators who intend to publish their findings, accelerating a move in the industry to provide greater transparency to the public. But the pharma giant's "independent experts" selected to run the program include at least two people with close ties to GSK.
